Report overview
Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers.
This report contains market size and forecasts of Malignant Glioma Drugs in global, including the following market information:
Global Malignant Glioma Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Malignant Glioma Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Malignant Glioma Drugs companies in 2021 (%)
The global Malignant Glioma Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Alkylating Agents Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Malignant Glioma Drugs include Merck, Eli Lilly, AbbVie, Bristol-Myers Squibb, Genentech, Sun Pharmaceutical, BioMimetix, Cipla and Sigma-Aldrich, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Malignant Glioma Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Malignant Glioma Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Malignant Glioma Drugs Market Segment Percentages, by Type, 2021 (%)
Alkylating Agents
VEGF/VEGFR Inhibitors
Anti Angiogenic Drugs
Global Malignant Glioma Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Malignant Glioma Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
Cancer Research Organizations
Diagnostic Centers
Others
Global Malignant Glioma Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Malignant Glioma Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Malignant Glioma Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Malignant Glioma Drugs revenues share in global market, 2021 (%)
Key companies Malignant Glioma Drugs sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Malignant Glioma Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Eli Lilly
AbbVie
Bristol-Myers Squibb
Genentech
Sun Pharmaceutical
BioMimetix
Cipla
Sigma-Aldrich
Panacea Biotec
Zydus Cadila
